The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Rosario Garcia Campelo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche/Genentech
 
Manuel Cobo
No Relationships to Disclose
 
Celine Mascaux
Honoraria - Astrazeneca; Bristol-Myers Squibb; Janssen; Kephren; MSD; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Kephren; MSD; Pfizer; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - MSD
(OPTIONAL) Uncompensated Relationships - Boehringer Ingelheim
 
Anne Madroszyk
No Relationships to Disclose
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Werner Hilgers
Honoraria - MSD Oncology
Consulting or Advisory Role - AstraZeneca; Janssen
 
Giampiero Romano
No Relationships to Disclose
 
Fabrice Denis
Stock and Other Ownership Interests - Kelindi (Inst)
Honoraria - AstraZeneca; Ipsen; MSD; Pfizer/EMD Serono; Roche Belgium; Takeda
Consulting or Advisory Role - SIVAN Innovation (Inst)
Other Relationship - Chugai Pharma; Ferring; Ipsen; Janssen-Cilag; Merck Serono; Novartis; Takeda
 
Santiago Viteri Ramirez
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Merck KGaA; Puma Biotechnology; Reddy Pharma Iberia; Roche; Takeda
Speakers' Bureau - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Merck KGaA; Merck KGaA; MSD; Roche
 
Didier Debieuvre
Honoraria - AstraZeneca; BMS France; GlaxoSmithKline; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; BMS France; Ipsen; Janssen; MSD Oncology; Novartis; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS france (Inst); Boehringer Ingelheim (Inst); Chiesi (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS france; BMS france; BMS France; Boehringer Ingelheim; Boehringer Ingelheim France; Lilly (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; novartis France; Pfizer; Roche; Roche; Takeda
 
Mohammad Razaq
No Relationships to Disclose
 
Wolfgang Schuette
Honoraria - MSD; Novartis; Roche
Consulting or Advisory Role - MSD; Novartis; Roche
 
Alona Zer
Stock and Other Ownership Interests - Nixio
Honoraria - AstraZeneca; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Lilly O.; MSD; Oncotest/Rhenium; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Pierre Attali
Leadership - Orphelia Pharma; Quantificare
Stock and Other Ownership Interests - Onxeo; Sanofi; Sensorion
Honoraria - OSE Immunotherapeutics
Consulting or Advisory Role - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - Clonidine Buccal tablet; Doxorubicine transdrug
 
François Montestruc
Leadership - eXYSTAT
Consulting or Advisory Role - Abbvie; Biocodex; Geneuro; GenSight Biologics; Guerbet; Imcheck Therapeutics; OSE Immunotherapeutics; Pfizer; Takeda
(OPTIONAL) Uncompensated Relationships - Institut Pasteur
 
Berangere Vasseur
Employment - OSE Immunotherapeutics
Stock and Other Ownership Interests - OSE Immunotherapeutics
Patents, Royalties, Other Intellectual Property - Patent "USES OF ANTI-SIRPa ANTIBODIES IN THE TREATMENT OF CANCER"
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Giuseppe Giaccone
Consulting or Advisory Role - Daiichi; Eisai; Janssen Oncology; Novartis; Radiomics; Sanofi; Sanofi/Regeneron; Spectrum Pharmaceuticals
Research Funding - Cantargia AB (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst)